Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

Inclusion Criteria:

• On maintenance treatment with either liraglutide 3.0 milligram (mg) for at least 5 days, oral semaglutide 25 mg for at least 5 weeks or semaglutide 2.4 mg for at least 5 weeks prior to screening.

Exclusion Criteria:

• Previous dosing in this study.

• Previous rescreening for this study.

• Female who is pregnant, breast-feeding or intends to become pregnant or is ofchildbearing potential and not using adequate contraceptive method

• Current participation (i.e., signed informed consent) in any other interventionalclinical study.

• Exposure to investigational medicinal products, except maintenance treatment withliraglutide 3.0 mg, oral semaglutide 25 mg, or semaglutide 2.4 mg as required by theinclusion criterion, within 30 days or 5 half-lives of the investigational medicinalproduct (if known), which-ever is longer, before screening (Visit 1).

• Any condition which in the investigator's opinion might jeopardise participant'ssafety or compliance with the protocol.

• Anticipated change in lifestyle (e.g., eating, exercise or sleeping pattern) duringthe study.

• Participant is the investigator or other site staff or relative thereof directlyinvolved in the conduct of the study.

• Mental incapacity, language barriers or unwillingness to comply with therequirements of the protocol, which may preclude adequate understanding orco-operation during the study as judged by the investigator.

• Presence of clinically significant gastrointestinal disorders or symptoms ofgastrointestinal disorders potentially affecting absorption of drugs or nutrients,or as judged by the investigator.

• History of major surgical procedures involving the oesophagus or stomach potentiallyaffecting absorption of trial products (e.g. subtotal and total gastrectomy, sleevegastrectomy, gastric bypass surgery) or current presence of gastrointestinal implanta*.

• Renal impairment with estimated glomerular filtration rate (eGFR) less than (<) 30milliliter per min per 1.73 square meter (ml/min/1.73 m^2) at screening based on theChronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equationaccording to Kidney Disease Improving Global Outcomes (KDIGO) 20246.

• Current treatment with insulin or secretagogues that might cause hypoglycaemiaduring periods of fasting.

• History of ketoacidosis.

• Diagnosed with or suspected to suffer from clinically significant gastroparesis,hiatal hernia or severe gastroesophageal reflux diseases with daily symptoms and/orin supine position.

• Use of other medications known to affect the motility of the stomach.

• Inability to lie in the right lateral decubitus position for gastricultrasonography.

• Unusual meal habits and special diet requirements or unwillingness to eat the mealsprovided in the study.

1. As declared by the participant or reported in the medical records.